Entity family

Browse treatments

Clinical therapies and care approaches used to manage a condition. Examples include immunotherapy, radiotherapy, rehabilitation.

19articles mentioning treatments

27treatment mentions

1distinct treatments extracted

0%of mentions human-reviewed

Active filtersEntity: anti-PD-1 therapy ×

anti-PD-1 therapy

This treatment is selected. Its supporting articles are shown below.

anti-PD-1 therapy19

Articles mentioning anti-PD-1 therapy

19 articles · page 2 of 2

111 Unsupervised clustering analysis identifies novel immune cell population in melanoma patients treated with anti-PD-1 therapy

jitc · abstract · 2025-11-04 · 1 matching annotations

86.0%

anti-PD-1 therapy Huntsman Cancer Institute checkpoint inhibitors Hunstman Cancer Institute melanoma

…mples from 29 melanoma patients (70 samples total) treated with anti-PD-1 therapy at the Huntsman Cancer Institute. Using a 43-marker mass cytome…

1225 Inhibition of MGAT1 overcomes STK11-driven immune evasion in non-small cell lung cancer

jitc · abstract · 2025-11-04 · 1 matching annotations

77.9%

anti-PD-1 therapy NSCLC non-small cell lung cancer Checkpoint inhibitors

…models in mice to identify targets which restore sensitivity to anti-PD-1 therapy.Results Knockout of MGAT1, an enzyme critical for maturation of…

493 Akkermansia muciniphila reprograms immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti-PD-1 therapy in MSS colorectal cancer: phase I trial

jitc · abstract · 2025-11-04 · 1 matching annotations

76.5%

immunotherapy anti-PD-1 therapy West China Hospital of Sichuan University Institutional Review Board CRC Akk ClinicalTrials.gov MSS CRC

…s with higher Akk abundance showed better clinical responses to immunotherapy. The phase I trial (N=20) demonstrated favorable safety: 70% (1…

494 Akkermansia muciniphila reprograms immunosuppressive microenvironment via efferocytosis inhibition to sensitize anti-PD-1 therapy in MSS colorectal cancer: phase I trial

jitc · abstract · 2025-11-04 · 1 matching annotations

75.4%

immunotherapy anti-PD-1 therapy West China Hospital of Sichuan University Akk Institutional Review Board CRC ClinicalTrials.gov MSS CRC

…s with higher Akk abundance showed better clinical responses to immunotherapy. The phase I trial (N = 22) demonstrated favorable safety: 86% …

658 KAN-001, a defined live biotherapeutic product (LBP) for NSCLC, enhances ICI response in preclinical models and demonstrates manufacturing consistency and strain-resolved viability

jitc · abstract · 2025-11-04 · 1 matching annotations

82.6%

anti-PD-1 therapy PD-1 therapy MD Anderson Cancer Center KAN-001 non-small cell lung cancer NSCLC CRCHUM Canadian Council

… evaluated in the MCA205 murine tumor model in combination with anti-PD-1 therapy. Comparative arms included treatment with FMT from ICI-non-resp…

Hypoxia-induced RCOR2 promotes macrophage M2 polarization and CD8+ T-cell exhaustion by enhancing LIF transcription in hepatocellular carcinoma

jitc · abstract · 2025-10-05 · 1 matching annotations

78.7%

anti-PD-1 therapy hepatocellular carcinoma HCC REST corepressor 2 (RCOR2)RCOR2

…identifies novel biomarkers associated with tumor resistance to anti-PD-1 therapy. This study provides potential therapeutic targets for HCC.…

Characterisation of systemic lupus erythematosus associated with immune checkpoint inhibitors: a pharmacovigilance study using FAERS database

lupusscimed · abstract · 2025-09-29 · 1 matching annotations

79.9%

anti-programmed death-ligand 1 therapy anti-PD-1 therapy chemotherapy SLE lung cancer breast cancer melanoma SLEs cutaneous lupus

…articularly for anti-programmed cell death protein 1 (PD-1) and anti-programmed death-ligand 1 therapy. Eight positive signals of SLEs were identified, predominantly …